St. Paul, Minnesota - Agitated Solutions, Inc., a medical technology company developing tools to improve ultrasound imaging and aid in diagnosis across multiple clinical applications, has announced the first patient enrollment in its Phase 3 clinical trial. The multicenter, randomized “ENHANCE” study is focused on assessing the safety and efficacy of ASI-02 in patients undergoing transthoracic echocardiography (TTE) with agitated saline contrast—commonly referred to as a "cardiac bubble study”—in the United States and Canada. The first patient was enrolled at Northwestern University.

St. Paul, Minnesota - Agitated Solutions, Inc. (ASI), a medical technology company developing innovative tools to enhance ultrasound imaging and diagnostic accuracy across multiple clinical applications, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its inaugural product, ASI-02.

St. Paul, Minnesota - The U.S. Food and Drug Administration (FDA) has cleared Agitated Solutions, Incorporated (ASI)’s Investigational New Drug (IND) application for its novel contrast agent, ASI-02, enabling the initiation of the company’s Phase 3 clinical trial.